HORIBA expands instrument offerings to support the drug pipeline from discovery to manufacturing
Providing a portfolio of instruments tailored to meet the rigorous demands of the pharmaceutical industry
12 Mar 2025Industry news
HORIBA has expanded its pharmaceutical and biopharmaceutical analysis portfolio with two new instruments launched at Pittcon Conference and Exposition 2025, strengthening its support for drug discovery, development, manufacturing, and quality control workflows worldwide. The enhanced suite of technologies is designed to help pharmaceutical and biopharma companies meet stringent regulatory requirements, improve process efficiency, and ensure the safety and quality of drug products.
Comprehensive solutions across the pharmaceutical lifecycle

HORIBA’s current suite of offerings spans the entire pharmaceutical lifecycle, from early-stage drug discovery and development through to large-scale manufacturing and quality control. These technologies are engineered to meet the rigorous demands of pharmaceutical and biopharmaceutical processes, supporting precision, efficiency, and compliance in regulated environments.
Key application areas include:
- Cell culture media analysis: Accurate monitoring of cell culture environments to optimize biopharmaceutical production.
- Vaccine development: Advanced analytical tools for formulation and quality control to streamline vaccine research, manufacturing, and QA/QC.
- Protein and biomolecule characterization: Precise measurement and analysis of molecular interactions critical for therapeutic development.
- Particle size and morphology: Understanding and ensuring dynamics, consistency, and quality in pharmaceutical formulations.
- Contaminant detection: Safeguarding the integrity of drug products by identifying and quantifying impurities.
New Veloci A-TEEM BioPharma Analyzer for biopharma and pharma
HORIBA has introduced the Veloci™ A-TEEM BioPharma Analyzer, a dedicated solution for the biopharma and pharma industries that combines the selectivity of chromatography with the advantages of optical spectroscopy. This analyzer is designed to provide a fast, cost-effective, and user-friendly approach to component analysis, removing the need for traditional column-based separations in many workflows.
Veloci uses label-free intrinsic fluorescence analysis to deliver high-precision, high-efficiency measurements across a wide range of biopharmaceutical applications, including:
- Monoclonal antibody discrimination
- Cell media monitoring
- Vaccine characterization
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How is HORIBA expanding its pharmaceutical and biopharmaceutical analysis portfolio with new instruments launched at Pittcon Conference and Exposition 2025?
HORIBA has expanded its pharmaceutical and biopharmaceutical analysis portfolio by launching two new instruments at Pittcon Conference and Exposition 2025. These additions strengthen HORIBA’s support for drug discovery, development, manufacturing, and quality control workflows worldwide. The enhanced suite of technologies is designed to help pharmaceutical and biopharma companies meet stringent regulatory requirements, improve process efficiency, and ensure the safety and quality of drug products across the entire pharmaceutical lifecycle.
What is the Veloci A-TEEM BioPharma Analyzer and how does it support biopharma and pharma applications?
The Veloci A-TEEM BioPharma Analyzer is a dedicated solution introduced by HORIBA for the biopharma and pharma industries. It combines the selectivity of chromatography with the advantages of optical spectroscopy to provide a fast, cost-effective, and user-friendly approach to component analysis, often removing the need for traditional column-based separations. Using label-free intrinsic fluorescence analysis, Veloci delivers high-precision, high-efficiency measurements for applications such as monoclonal antibody discrimination, cell media monitoring, and vaccine characterization.
What key pharmaceutical and biopharmaceutical application areas are supported by HORIBA’s analytical technologies?
HORIBA’s analytical technologies support key application areas across the pharmaceutical lifecycle, including cell culture media analysis for optimizing biopharmaceutical production, vaccine development with advanced tools for formulation and QA/QC, protein and biomolecule characterization for precise analysis of molecular interactions, particle size and morphology assessment to ensure consistency and quality in formulations, and contaminant detection to safeguard the integrity of drug products. These solutions are engineered to meet the rigorous demands of regulated pharmaceutical and biopharmaceutical environments.